XNAS
RTSN
, Last price
USD
Name
Retension Pharmaceuticals Inc.
Chart & performance
P/E
—
P/S
—
EPS
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
Net income
CFO
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Key people
Eric Keller
Chairman of the Management Board, Chief Executive Officer, Founder, Director
Ben de La Cretaz
Chief Financial Officer
Sabine Bisson
Chief Operations Officer
Paul Sweetnam
Co-Founder, Chief Scientific Officer
Michael Berendt
Chairman of the Board
Valuation
No data to show